Quectel Breaks Ground for New Innovation Headquarters and Readies for Aggressive Growth Plans With Opening of Most Advanced Smart Factory
16.5.2023 19:25:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announces breaking ground for its new innovation Headquarter in Shanghai and also recently celebrated a significant milestone with the opening of its new Global Intelligent Manufacturing Center (GIMC) in Changzhou.
Delivering advanced IoT automation, the new GIMC facility features a fully functioning manufacturing production line that combines latest technologies, including edge intelligence, machine learning, robotics and machine vision solutions built with Quectel’s latest smart module technologies which significantly expands manufacturing capabilities to guarantee supply and reassure product quality for global customers. Designed and architected by a group of its own IoT experts, this state-of-the art IoT manufacturing center is equipped with the most advanced industrial automation technologies including:
- Fully automated warehouse storage system with 65,000 material cubicles, which can support 40 SMT lines material supply and operate 7x24 based on real-time workorders.
- End-to-end touchless process with Automatic Guided Vehicles to transport raw material to production lines, hand-over semi-products from SMT for testing and final packing with minimal manpower.
- 30 Fuji NXT-III SMT lines with Siemens MES monitoring system supporting production of up to 150 million modules per year.
- 85 Quectel Self Design Automatic Testing Stations with full testing log files onto each module produced.
- 40 Quectel Self Design Auto Inspection and Packing Systems.
The GIMC project started construction in September 2021 and will commence operation in 2023. The smart factory will further enhance Quectel’s production capabilities, strengthening its core competitiveness. The center occupies an area of 72,000 square meters, with a total construction space of 160,000 square meters. It is capable of manufacturing Quectel’s full range of modules, including 4G modules, 5G modules, smart modules, automotive grade modules, narrowband IoT modules, GNSS modules, Wi-Fi modules and antennas.
“Our new smart factory represents an important step toward the next generation of smart manufacturing and will guarantee both our product quality and production capacity, sufficient to meet various demanding requirements of our global customers,” said Patrick Qian, CEO of Quectel. “Applying IoT innovation to our own processes -- will not only help us enhance our industry leading quality -- it will also accelerate the expansion of the global IoT market and be a catalyst for the entire IoT eco-system.”
Quectel also recently broke ground for its new headquarters in Shanghai. “The new headquarter is designed to provide a modern, smart environment that makes it attractive for the best people to work, excel and innovate and that exceeds the highest standards in sustainability, health and wellness,” Mr. Qian continued.” It will host Quectel’s R&D center and IoT innovation showroom and will bring together some of the world’s greatest engineers and IoT leaders to accelerate innovation and drive the future of IoT”. The new headquarter of approximately 100,000 square meters will serve as a central hub for administrative and research and development functions but will also offer a wide range of amenities including sports facilities, conference spaces, outdoor gardens, catering services, and ample parking facilities. The company plans to officially inaugurate and begin operations at the new headquarters in 2025.
Founded in 2010, Quectel has consistently maintained rapid development and has become a leading global IoT provider of solutions covering cellular modules, Wi-Fi modules, smart modules, automotive modules, GNSS modules, antennas as well as connectivity and certification services.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 6,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas, services and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005801/en/
Contact information
Phil Rawcliffe, Head of Communications
phil.rawcliffe@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom